目的 探究參麥注射液聯(lián)合甲磺酸加貝酯治療急性胰腺炎的臨床療效。方法 選取2014年1月—2016年7月重慶市巴南區(qū)第二人民醫(yī)院收治的急性胰腺炎患者96例，隨機分為對照組和治療組，每組各48例。對照組在常規(guī)治療的基礎上靜脈滴注注射用甲磺酸加貝酯，前3 d 300 mg/d，3 d后100 mg/d。治療組患者在對照組的基礎上靜脈滴注參麥注射液40 mL/d，兩組均治療2周。觀察兩組的臨床療效，比較兩組的臨床癥狀改善及住院時間和血淀粉酶、尿淀粉酶、血白細胞（WBC）和血門冬氨酸氨基轉移酶（AST）及其不良反應情況。結果 治療后，對照組和治療組的總有效率分別為79.41%、91.67%，兩組比較差異具有統(tǒng)計學意義（P < 0.05）。治療后，治療組的腹痛緩解時間、腹部壓痛消失時間、住院時間和血淀粉酶恢復正常時間均短于對照組，兩組比較差異具有統(tǒng)計學意義（P < 0.05）。治療后，兩組患者的血淀粉酶、尿淀粉酶、血WBC和血AST均較治療前顯著降低，同組治療前后比較差異具有統(tǒng)計學意義（P < 0.05）；且治療組患者的上述觀察指標均明顯低于對照組，兩組比較差異具有統(tǒng)計學意義（P < 0.05）。兩組不良反應發(fā)生情況比較差異無統(tǒng)計學意義。結論 參麥注射液聯(lián)合甲磺酸加貝酯治療急性胰腺炎的療效顯著，安全性較高，具有一定的臨床推廣應用價值。

Objective To explore the curative effect of Shenmai Injection combined with gabexate mesilate in treatment of acute pancreatitis. Methods Patients (96 cases) with acute pancreatitis in the Second People's Hospital of Banan District in Chongqing from January 2014 to July 2016 were randomly divided into control and treatment groups, and each group had 48 cases. Patients in the control group were iv administered with Gabexate Mesilate for injection on the basis of conventional therapy, 300 mg/d on the three days before administration, and after three days the dosage was adjusted to 100 mg/d. Patients in the treatment group were iv administered with Shenmai Injection on the basis of the control group, 40 mL/d. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and the time of clinical symptoms improvement and hospitalization, blood amylase, urine amylase, WBC, AST, and adverse reactions in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 79.41% and 91.67%, respectively, and there was difference between two groups (P < 0.05). After treatment, remission time of abdominal pain, the disappearance time of abdominal tenderness, hospitalization time, and the time of blood amylase returned to normal was shorter than those in the control group, and there was difference between two groups (P < 0.05). After treatment, blood amylase, urine amylase, WBC, and AST in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And these observed indicators in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). There was no significant difference in adverse reactions between two groups. Conclusion Shenmai Injection combined with gabexate mesilate has clinical curative effect in treatment of acute pancreatitis with high safety, which has a certain clinical application value.